1 **<u>ChatGPT for assessing risk of bias of randomized trials using the RoB</u>**

2 **<u>2.0 tool: A methods study</u>**

4 Tyler Pitre
5  *Division of Respirology, Department of Medicine*
6  *University of Toronto*
7 Tanvir Jassal
8  *Departments of Anesthesia*
9  *McMaster University, Hamilton, ON*
10 Jhalok Ronjan Talukdar
11  *Departments of Anesthesia and Health Research Methods, Evidence, and Impact*
12  *McMaster University, Hamilton, ON*
13 Mahnoor Shahab
14  *Faculty of Health Sciences*
15  *McMaster University, Hamilton, ON*
16 Michael Ling
17  *Departments of Anesthesia*
18  *McMaster University, Hamilton, ON*
19 Dena Zeraatkar*
20  *Departments of Anesthesia and Health Research Methods, Evidence, and Impact*
21  *McMaster University, Hamilton, ON*
22

*Corresponding author:

**Disclaimers:** None.

**Funding**: None.

**Data:** Available on OSF (XX)

**Acknowledgements:** None.

**Authors' Contributions:** DZ and TP conceived this study. TJ, JRT, MS, and ML collected data. DZ and TP

analyzed the data. DZ and TP wrote the first draft of the manuscript and all authors reviewed and

approved the final version.

**Word count:** 5,918

**Tables:** 3

**Figures:** 3

**Abstract**

***Background:*** Internationally accepted standards for systematic reviews necessitate assessment of the
risk of bias of primary studies. Assessing risk of bias, however, can be time- and resource-intensive. AI-
based solutions may increase efficiency and reduce burden.

***Objective:*** To evaluate the reliability of ChatGPT for performing risk of bias assessments of randomized
trials using the revised risk of bias tool for randomized trials (RoB 2.0).

***Methods:*** We sampled recently published Cochrane systematic reviews of medical interventions (up to
October 2023) that included randomized controlled trials and assessed risk of bias using the Cochrane-
endorsed revised risk of bias tool for randomized trials (RoB 2.0). From each eligible review, we collected
data on the risk of bias assessments for the first three reported outcomes. Using ChatGPT-4, we
assessed the risk of bias for the same outcomes using three different prompts: a minimal prompt
including limited instructions, a maximal prompt with extensive instructions, and an optimized prompt
that was designed to yield the best risk of bias judgements. The agreement between ChatGPT's
assessments and those of Cochrane systematic reviewers was quantified using weighted kappa
statistics.

***Results:*** We included 34 systematic reviews with 157 unique trials. We found the agreement between
ChatGPT and systematic review authors for assessment of overall risk of bias to be 0.16 (95% CI: 0.01 to
0.3) for the maximal ChatGPT prompt, 0.17 (95% CI: 0.02 to 0.32) for the optimized prompt, and 0.11
(95% CI: -0.04 to 0.27) for the minimal prompt. For the optimized prompt, agreement ranged between
0.11 (95% CI: -0.11 to 0.33) to 0.29 (95% CI: 0.14 to 0.44) across risk of bias domains, with the lowest
agreement for the deviations from the intended intervention domain and the highest agreement for the
missing outcome data domain.

***Conclusion:*** Our results suggest that ChatGPT and systematic reviewers only have "slight" to "fair"
agreement in risk of bias judgements for randomized trials. ChatGPT is currently unable to reliably
assess risk of bias of randomized trials. We advise against using ChatGPT to perform risk of bias
assessments. There may be opportunities to use ChatGPT to streamline other aspects of systematic
reviews, such as screening of search records or collection of data.

## Background

The practice of evidence-based medicine demands knowledge of the best available evidence, which most often comes from rigorous systematic reviews and meta-analyses (1). Systematic reviews, however, are time- and resource-intensive (2-4). Empirical evidence suggests they typically require upwards of one year to complete and publish and many are outdated at or shortly following publication (3, 5).

One time- and resource-intensive component of systematic reviews is the assessment of risk of bias of primary studies—defined as the propensity for studies to systematically over- or underestimate treatment effects (6, 7). Risk of bias assessments are burdensome and time-consuming and demand specialized training (6, 7). Moreover, to reduce the opportunity for errors, guidance for conducting rigorous systematic reviews typically suggests authors assess risk of bias independently and in duplicate, adding to the complexity and workload of the process (6).

Many tools exist to assess the risk of bias of randomized trials (8, 9), examples of which include the tools from the Joanna Briggs Institute (10), the Jadad Scale (11), and the Critical Appraisal Skills Program (CASP) checklist (12). These tools, however, generally fall short compared to the most commonly used tool, the original Cochrane risk of bias tool for randomized trials, and their application is not recommended (6, 13, 14).

In 2019, a new risk of bias tool was introduced that built on the successes of the previous Cochrane endorsed risk of bias tool but also incorporated new advancements (15). This tool was called the revised tool for assessing risk of bias of randomized trials (RoB 2.0) and is now largely considered the gold standard (6).

The application of the RoB 2.0 tool, like other risk of bias tools, typically involves reviewers using trial reports and trial registrations or protocols, when available, to make judgements for each risk of bias domain (6, 15). Reviewers who collect data for a systematic review are also typically tasked with assessing the risk of bias of eligible trials (6). The RoB 2.0 tool rates risk of bias as either high, some concerns, or low across five domains: randomization, deviations from intended intervention, missing outcome data, measurement of outcome, and selective reporting. To guide judgements, the RoB 2.0 includes signaling questions for each domain. The overall rating of risk of bias is determined by the domain rated at highest risk of bias (6, 15).

While the RoB 2.0 tool builds off a decade's worth of experience with the original risk of bias tool, recent evidence suggests that reviewers find it complex and time-consuming—perhaps more complex and time-consuming than previous risk of bias tools (7, 16). Innovations to streamline and simplify risk of bias assessments without compromising their rigor will reduce the time and effort required to perform systematic reviews and aid in maintaining their currency.

RobotReviewer is an automated tool to extract data from and assess the risk of bias of randomized trials (17-19). Previous studies on RobotReviewer show optimistic results, with generally moderate to high agreement with systematic reviewers (70% to 90%) (17, 18). The RobotReviewer, however, was trained on the original Cochrane risk of bias tool, rather than the RoB 2.0 tool, and only offers judgements on four of the seven domains of the original tool. To our knowledge, RobotReviewer is the only artificial intelligence (AI) tool for assessing risk of bias in systematic reviews (20).

ChatGPT (OpenAI, San Francisco, California, USA) is a conversational AI large language model with
capabilities in natural language processing and realization (21). Differing from specialized automated
tools for risk of bias assessments, ChatGPT is a general purpose tool, has been developed to emulate
human language rather than risk of bias assessments, and has been trained on an internet-scale corpus
covering many areas of knowledge, rather than a small training set focused on evidence synthesis and
evaluation (21).

This study evaluates the performance of ChatGPT, an AI-based language model, for assessing risk of bias
of randomized trials using the RoB 2.0 tool. To do this, we sampled Cochrane systematic reviews using
the RoB 2.0 tool and used ChatGPT-4—an advanced large language model offered by OpenAI—to assess
the risk of bias of the trials within these reviews. We compared ChatGPT's assessment with those
presented in Cochrane reviews. Consistency in assessments of risk of bias between ChatGPT and
Cochrane reviewers will suggest that ChatGPT can provide a reliable assessment of the risk of bias of
randomized trials. Conversely, discrepancies in risk of bias assessments between ChatGPT and Cochrane
reviewers will suggest that ChatGPT is unreliable for assessing risk of bias.

**Methods**

We registered our protocol on Open Science Framework (https://osf.io/aq85p) in September 2023. We
report our study according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) and Guidelines for Reporting Reliability and Agreement Studies (GRRAS) reporting checklists
(22, 23).

This study does not involve human participants and is thus exempt from ethics review.

Figure 1 presents an overview of our methods.

*Search strategy and screening*
For this study, we intended to include a reasonably representative sample of Cochrane systematic
reviews. We did not perform a search of medical research databases. Instead, we used the Cochrane
Database of Systematic Reviews (CDSR) that provides a chronological catalogue of published and
updated Cochrane systematic reviews to identify eligible reviews.

Reviewers worked independently and in duplicate to screen Cochrane reviews for eligibility, starting
with the most recently published (August 2023) and working backwards in time. We preferentially
included the most recently published Cochrane systematic reviews since these reviews are most likely to
have used the most up-to-date version of the RoB 2.0 tool instead of preliminary pilot versions of the
tool (15). Reviewers continued screening until we had identified our target sample size of approximately
160 trials.

*Eligibility criteria*
Our sampling approach was designed to include randomized trials addressing a diverse range of
questions (i.e., selected from different systematic reviews) and both dichotomous and continuous
outcomes.

We included newly published or updated Cochrane systematic reviews addressing the benefits and/or
harms of health interventions that included one or more parallel randomized trials and reported
consensus-based risk of bias judgements using the Cochrane-endorsed RoB 2.0 tool (15). We defined

consensus-based as two reviewers agreeing on the final risk of bias judgements. This may involve two
reviewers independently assessing risk of bias and resolving conflicts by discussion or a reviewer
assessing risk of bias and a second reviewer confirming the first reviewers' judgements.

We excluded systematic reviews that were not published by Cochrane, since such reviews may not
involve reviewers with sufficient training to appropriately apply the RoB 2.0 tool. We also excluded
Cochrane systematic reviews that investigated prognosis or the performance of diagnostic tests and
systematic reviews that only included observational studies since these reviews will necessitate the use
of other risk of bias tools.

Cochrane systematic reviews use summary of findings tables to present their results (6, 24). These tables
list outcomes in order of importance, the number of trials and patients that contributed data to the
meta-analysis for each outcome, the relative and absolute effect estimates based on meta-analyses, and
judgements about the certainty of evidence (6, 24). From each eligible review, we selected the first two
listed outcomes (suggesting that they are the most important) that were informed by one or more trials.
If either of the first two outcomes were continuous, we then selected the third outcome listed in the
summary of findings table. If the two reported outcomes were both dichotomous, we then selected the
first listed continuous outcome reported in the summary of findings table. When summary of findings
tables reported on the same outcome at different timepoints, we selected entirely unique outcomes.

From each review, we included all parallel randomized trials published in English that were included in
analyses addressing the outcomes of interest. We excluded crossover and cluster randomized trials
since these trial designs require unique considerations in their assessment of risk of bias and different
versions of the RoB 2.0 tool. Cochrane reviews often include unpublished trial data. When reviews
reported that information for a particular trial was unpublished or was drawn from a combination of
unpublished and published data, we excluded those trials since we did not have access to the same
unpublished information as the Cochrane reviewers for risk of bias assessments.

For feasibility, we also excluded trials for which data were drawn from multiple publications. Including
such trials would have necessitated an exhaustive review of all related publications to identify those
containing the outcome data and the comprehensive details required for risk of bias assessment.

***ChatGPT prompts***
A key component in the use of ChatGPT is the design of the text used to instruct the model (called
'prompts') to generate an answer. We anticipated that ChatGPT's risk of bias judgements may depend
on the nature of the prompts that it is provided. To study how different prompts may influence risk of
bias judgements, we iteratively designed three different prompts: a minimal prompt including limited
instructions for assessing risk of bias, a maximal prompt with extensive instructions, and an optimized
prompt that was designed to include sufficient information to yield the best risk of bias judgements.

We piloted the prompts using 15 trials drawn from systematic reviews previously performed by our own
team and refined the prompts by iterative discussion and input by the co-authors (25-27). All prompts
asked ChatGPT to judge risk of bias for all RoB 2.0 domains (bias due to randomization, deviation from
intended intervention, missing outcome data, measurement of outcome, and selective reporting) as low
risk of bias, some concerns, or high risk of bias—consistent with RoB 2.0 guidance (15). Supplement 1
presents these three prompts.

The RoB 2.0 tool is accompanied by a document that describes the tool and offers guidance on its
implementation. All three prompts included the RoB 2.0 full guidance document (riskofbias.info), which
were fed to ChatGPT using the AskYourPDF ChatGPT plugin that allows ChatGPT to read and query PDF
documents. All prompts also included a PDF copy of the trial publication, a PDF copy of the trial
registration or protocol (if one was available), and specified the outcome of interest for which risk of
bias assessment was being performed. The prompts also specified the order in which the RoB 2.0
domains should be assessed and that the responses should include a judgment and rationale.

The RoB 2.0 tool offers two options for assessing the risk of bias due to deviations of the intended
intervention: one for the effect of assignment to the intervention and the other for the effect of
adhering to the intervention. In Cochrane systematic reviews, the subsection on risk of bias typically
reports whether Cochrane reviewers assessed risk of bias for the effect of assignment or adherence to
the intervention. Our ChatGPT prompts also specified whether to assess risk of bias for the effect of
assignment or adherence to the intervention. We specified the same option used by the Cochrane
systematic reviews. For systematic reviews that failed to specify whether they assessed risk of bias for
the effect of being assigned to the intervention or adherence to the intervention, we assumed they
assessed risk of bias for assignment to the intervention.

The ChatGPT prompts do not include any information related to the consensus-based risk of bias
judgements presented in the systematic reviews. Hence, ChatGPT is 'blind' to the Cochrane systematic
reviewers' risk of bias judgements.

***Data collection***
RoB 2.0 guidance demands that reviewers perform risk of bias judgements for each particular result
rather than each trial or outcome, since risk of bias may differ across outcomes in a trial or across
different ways of statistically summarizing the results for the same outcome (15). We took this approach
in this study. For each eligible trial and outcome, we collected information on the consensus-based risk
of bias judgements presented in the Cochrane systematic reviews. Subsequently, for each eligible trial,
we used the ChatGPT-4 chatbot to assess the risk of bias of the outcomes of interest, using each of the
three ChatGPT prompts. ChatGPT-4 is a more advanced iteration of its predecessor ChatGPT-3. Unlike
ChatGPT-3, ChatGPT-4 is only available with a paid subscription to OpenAI. We implemented each of the
prompts in unique chats.

We did not collect data in duplicate because the nature of the data did not require any subjective
judgements and we anticipated that the only potential source of error is mistakes in copying and pasting
prompts to the ChatGPT interface, which we deemed unlikely.

We anticipated that the reliability of ChatGPT may depend on the objectivity of the outcome for which
risk of bias is being assessed. We considered outcomes objective if they were based on established
laboratory measures or if they were not subject to interpretation by patients or healthcare providers.
Conversely, we considered outcomes subjective if they were patient-reported or subject to
interpretation by patients or healthcare providers. We classified outcomes as either objective (e.g.,
mortality), probably objective (e.g., unscheduled physician visits), probably subjective (e.g., serious
adverse events), and definitely subjective (e.g., quality of life) to facilitate stratified analyses based on
the degree of objectivity of the outcome.

***Data synthesis and analysis***

<u>Sample size estimation</u>

We used the kappaSize package in R (Vienna, Austria, Version 4.1.3) to estimate sample size (28). We

aimed to calculate the number of required trials to obtain a sufficiently precise estimate of a value of

kappa for which systematic reviewers will feel confident using ChatGPT for risk of bias assessments. We

assumed that most reviewers would feel confident using ChatGPT for risk of bias assessments if it yields

a kappa of 0.70, indicating substantial agreement, with the lower bound of the confidence interval no

less than 0.55. We anticipated the risk of bias distribution to be approximately 30% low, 30% with some

concerns, and 40% high.

We inflated the estimated sample size by a design effect to account for correlation between the risk of

bias of trials from the same review. We assumed an intra-review correlation of 0.05 and an average of

10 trials per review, yielding a design effect of 1.45. This resulted in a minimum sample size of 120 trials

from 12 reviews. We investigated the sensitivity of our estimated sample size to different assumptions

about the anticipated distribution of risk of bias judgements across the three categories and the

potential correlation between trials from the same review. To account for other potential scenarios

(e.g., kappa = 0.6, intrareview correlation of 0.1), we ultimately intended to include approximately 160

trials from 16 reviews.

<u>Agreement between ChatGPT and consensus-based risk of bias assessments</u>

We present the inter-rater agreement, represented by weighted kappa, between each of the three

ChatGPT prompts and consensus-based risk of bias judgements from Cochrane authors. Unlike

percentage agreement, the weighted kappa accounts for the possibility of agreement due to chance and

for the ordinal nature of the response options of the RoB 2.0 tool (low risk of bias, some concerns, high

risk of bias) (29).

We present separate analyses for each RoB 2.0 domain and for the overall rating of risk of bias. Each

analysis only includes one outcome from each included trial. Our primary analysis includes the most

important outcome, based on the order in which outcomes were listed in Cochrane systematic review

summary of findings tables. We adjusted for clustering of trials within each systematic review by

inflating the variance of all estimates by the design effect (30).

We interpreted Cohen's kappa statistics using previously established guidelines: values from 0.0 to 0.2

indicating slight agreement, 0.21 to 0.40 indicating fair agreement, 0.41 to 0.60 indicating moderate

agreement, 0.61 to 0.80 indicating substantial agreement, and 0.81 to 1.0 indicating perfect agreement

(31).

We hypothesized that ChatGPT may be more reliable to assess risk of bias when there are few subjective

judgements. Therefore, we expected better agreement for: (i) trials addressing pharmacologic

interventions because trials of pharmacologic interventions are more likely to blind patients and

healthcare providers thus simplifying judgements related to deviations from intended intervention and

measurement of outcomes; (ii) trials addressing risk of bias of assignment of the intervention because

assignment to the intervention does not necessitate making judgements about adherence; (iii) objective

outcomes since these outcomes do not need additional judgements about whether failure to blind may

have resulted in differential measurement of the outcome, and (iv) dichotomous instead of continuous

outcomes since continuous outcomes are more likely to be subjective. To test these hypotheses, we
performed secondary analyses stratified by these factors.

We also performed a secondary analysis in which we collapsed ratings of "some concerns" and "high risk
of bias" into a single category.

We performed all statistical analyses using the psych package in R (Vienna, Austria, Version 4.1.3) (32).

Review of ChatGPT justifications for discrepant risk of bias judgements between Cochrane systematic
reviewers and ChatGPT
Our prompts queried ChatGPT to provide a justification for its ratings of risk of bias. To understand
reasons why ChatGPT may produce unreliable risk of bias judgements, we also qualitatively reviewed
justifications provided by ChatGPT to support its judgements for potential errors or problems.

**Results**

*Systematic review and trial characteristics*
We included 157 trials from 34 systematic reviews. Figure 2 presents the selection of systematic
reviews. Supplement 2 presents a list of included reviews and supplement 3 presents a list of excluded
reviews.

More than half of reviews were published in 2023 and addressed pharmacologic interventions. Reviews
most addressed infectious, ophthalmologic, and respiratory conditions. Reviews either rated the risk of
bias for assignment to the intervention or did not report whether they assessed the risk of bias of
assignment to or adherence to the intervention. More than half of included outcomes were
dichotomous and rated as either definitely or probably objective.

In our analyses, each trial contributed data only for one outcome. Our primary analysis included data
from 157 trials. Of these, 45 (28.7%) were rated at low risk of bias overall by Cochrane systematic
reviewers, 75 (47.8%) at some concerns, and 37 (24.6%) at high risk of bias. Fifty-two trials (33.1%) were
rated at high risk of bias or some concerns for bias due to randomization, 37 (23.6%) for bias due to
deviations from the intended intervention, 23 (14.7%) for missing outcome data, 29 (18.5%) for
measurement of the outcome, and 72 (45.9%) for selective reporting.

*Agreement between ChatGPT and consensus-based risk of bias judgements from Cochrane review*
*authors*
In our analyses, each trial contributed data only for one outcome. When a trial reported data on more
than one outcome of interest, we included data for the outcome reported first in the systematic review.

We found overall only slight agreement between ChatGPT risk of bias judgements and consensus-based
risk of bias judgements from systematic reviewers. Agreement for overall risk of bias ranged between
0.11 (95% CI: -0.04 to 0.27) and 0.17 (95% CI: 0.02 to 0.32) for the minimal and optimized prompts,
respectively. Figure 2 presents a flow diagram representing categorical changes in the overall rating of
risk of bias between systematic reviewers and the optimized ChatGPT prompt.

For the optimized prompt, agreement ranged between 0.11 (95% CI: -0.11 to 0.33) to 0.29 (95% CI: 0.14
to 0.44) across risk of bias domains, with the lowest agreement for the deviations from the intended
intervention domain and the highest agreement for the missing outcome data domain.

We did not find evidence that ChatGPT had importantly different reliability in stratified analyses based
on whether trials addressed pharmacologic or non-pharmacologic interventions, objective or subjective
outcomes, dichotomous or continuous outcomes or whether reviews specified assessing the risk of bias
of assignment to the intervention (Supplements 4 to 10). ChatGPT showed "slight" to "fair" agreement
for these subgroups.

Likewise, our secondary analysis that collapsed ratings of "some concerns" and "high risk of bias" into a
single category also showed "slight" to "fair" agreement (Supplement 11).

Supplement 12 presents qualitative observations about discrepant risk of bias judgements between
ChatGPT and Cochrane systematic reviewers.

**Discussion**

*Main findings*
We performed a study evaluating ChatGPT for assessing the risk of bias of randomized trials using the
Cochrane-endorsed RoB 2.0 tool (15). To do this, we sampled Cochrane systematic reviews that
reported RoB 2.0 judgements for randomized trials, assessed the risk of bias of trials using ChatGPT via
three variations of prompts, and compared the degree of agreement between RoB 2.0 judgements
presented in systematic reviews and those by ChatGPT.

We found only slight to fair agreement between ChatGPT risk of bias judgements and those presented in
systematic reviews. Our results suggest that ChatGPT, at least as it stands today, is suboptimal for
facilitating risk of bias assessments. We found similar results when we restricted our analysis to
subgroups for which we hypothesized that ChatGPT may be more reliable, including trials addressing
pharmacologic interventions, reviews assessing the risk of bias associated with assignment to the
intervention, objective outcomes, and dichotomous outcomes.

We also reviewed cases in which ChatGPT's risk of bias judgements differed from those of Cochrane
systematic reviewers with the goal of identifying ways in which we can refine future prompts. Our
findings indicate that ChatGPT might make more accurate risk of bias judgements if informed about
both low and high risk of bias methodological traits. For example, one trial reported randomization by
an "interactive web-response system", which suggests central randomization and allocation
concealment (33). ChatGPT, however, rated the trial at some concerns for randomization because the
trial report "does not explicitly mention whether the allocation sequence was concealed". Training
ChatGPT to recognize features of trials at low versus high risk of bias may improve the reliability of its
risk of bias assessments.

Though our results appear discouraging, they must also be contextualized considering general poor
agreement between even experienced reviewers in implementing the RoB 2.0 tool. For example, a
previous investigation of the reliability of RoB 2.0 using experienced systematic reviewers reported
inter-rater reliability ranging between 0.04 to 0.45, indicating only slight to fair agreement (16). The
original Cochrane risk of bias tool also demonstrated poor inter-rater reliability for select domains (34).

Our results may also be explained by ChatGPT's limited memory, which may not be sufficient to fully
process RoB 2.0's extensive and lengthy guidance (35, 36). An improvement in ChatGPT's performance
in risk of bias assessment might be achieved by enhancing its memory capabilities, by utilizing other

plans from OpenAI that offer expanded memory options such as ChatGPT Enterprise, or by fine-tuning
ChatGPT's base model—a process that involves additional training of the model.

Finally, while we evaluated the degree of agreement between risk of bias judgements reported in
systematic reviews and those made by ChatGPT, we did not consider the impact of these discrepancies.
For example, discrepancies in risk of bias judgements may not necessarily lead to an overall change in
the rating of the certainty (quality) of evidence and the material conclusions of systematic reviews.

### Strengths and limitation
The primary strength of our study is its generalizability to diverse research questions, reviews, and
research teams. Risk of bias judgements are subjective and different research groups and teams may
have different understandings and thresholds for expressing concerns about risk of bias. Similarly,
assessing risk of bias involves unique considerations related to the research question being investigated.
As our sample included systematic reviews from multiple diverse research teams, ChatGPT's reliability is
not confined to the specific nuances of a single group's approach to risk of bias assessments or to a
single topic.

Our study was limited to parallel randomized trials published in English. We excluded crossover and
cluster randomized trials since these trial designs require unique considerations in their assessment of
risk of bias and different versions of the RoB 2.0 tool. Thus, the results of our study may lack
generalizability beyond English language parallel randomized trials, though these are the most common
studies typically included in systematic reviews. Further, it is unlikely for ChatGPT to be able to perform
remarkably differently for other types of trials, since assessing the risk of bias of these trials necessitates
the same considerations as parallel randomized trials in addition to several other unique considerations.

Evidence suggests that risk of bias assessments in Cochrane reviews, despite their rigor, are sometimes
unreliable and inconsistent with established guidance (16). Hence, differences in risk of bias judgements
between ChatGPT and Cochrane systematic reviewers may also represent errors on part of reviewers.
Previous studies suggest that agreement between reviewers in assessing risk of bias may be very poor
(37, 38). To minimize the potential for this error, we limited our sample to Cochrane systematic reviews,
which are known for their methodological rigor (39, 40).

The performance of ChatGPT is also not static. The infrastructure, interfaces, and applications built
around ChatGPT are continuously updated (35, 41, 42). Our experiment was performed over a two-week
time period between September and October 2023. It is possible that the performance that we
observed may not be replicable in the future—though it is more likely that the capabilities of ChatGPT
will improve rather than deteriorate. Even with identical prompts, ChatGPT might provide slightly
different answers due to the inherent stochasticity in its response generation (41).

The reliability of ChatGPT risk of bias assessments is likely to depend on the nature of the prompts. We
tested three different prompts. Our results suggest that the performance of the three prompts is
comparable. It is possible that reviewers may be able to produce more reliable risk of bias assessments
using alternative prompts.

Our prompts queried ChatGPT to provide a justification for its ratings of risk of bias. To understand
reasons why ChatGPT may produce unreliable risk of bias judgements, we also reviewed justifications
provided by ChatGPT to support its judgements for potential errors or problems. While we performed a

general review of justifications for which ChatGPT and Cochrane reviewers made discrepant risk of bias
judgements, we did not perform a formal qualitative analysis of the justifications.

While we did not record the exact duration our team spent using ChatGPT, we estimate that each trial
took no longer than 15 minutes—less time than on average required for a reviewer to conduct an
individual risk of bias assessment and consensus meeting according to empirical evidence (7, 16).

Finally, our systematic review includes minor deviations from the protocol. To account for correlation
between trials in the same systematic review, we planned to calculate weighted kappa within each
review individually and pool the weighted kappa statistics across systematic reviews using random-
effects meta-analysis (43). The sampling distribution of kappa, however, is asymmetric. While with a
large enough number of observations, the sampling distribution of kappa is approximately normal, we
found there to be too few trials within each systematic review to assume normality, precluding our
approach to perform meta-analyses. Instead, we adjusted the variance of all estimates for the
correlation within each systematic review. Likewise, in our primary analysis, we excluded ratings of
uncertain risk of bias from analyses. We had planned to perform additional sensitivity analyses treating
these ratings as some concerns or high risk of bias but there were too few uncertain ratings to affect
estimates of reliability.

***Relation to previous findings***
Attempts to reduce the time, resources, and expertise needed to perform systematic reviews are not
new. For example, RobotReviewer is an automated tool to extract data from and assess the risk of bias
of randomized trials (17). The RobotReviewer, however, was trained on the original Cochrane risk of bias
tool and only offers judgements on four of the seven domains of the original tool. Since then, Cochrane
has adopted a revised risk of bias assessment tool that requires more nuanced judgements and is more
resource- and time-intensive (7). Given the performance of ChatGPT, however, adapting RobotReviewer
to provide risk of bias assessments using the RoB 2.0 tool may be more promising.

***Implications***
Our results suggest that ChatGPT, in its current form, is not able to reliably assess the risk of bias of
randomized trials. Since assessment of the risk of bias of observational and diagnostic studies is even
more complicated, it is reasonable to expect that ChatGPT might encounter even more challenges with
these other types of study designs.

Our study also has implications for future research. Since the completion of this study, OpenAI has
released the option to create custom GPTs (42). Custom GPTs offer users the option to customize their
ChatGPT using additional instructions. While our prompts in their current form could not be used to
reliably assess risk of bias, other prompts or custom GPTs may be able to provide more reliable
assessments.

Further, more granular prompts may also lead to more reliable judgements. For example, for each
domain, RoB 2.0 contains a series of signaling questions designed to help reviewers think systematically
about the different aspects of trial conduct that might lead to bias. These signaling questions are
answered with "Yes," "Probably yes," "Probably no," "No," or "No information." Based on the answers to
these questions, a judgment is made about the risk of bias for that domain as "Low," "Some concerns,"
or "High." Instead of asking ChatGPT to assess the risk of bias of each domain, ChatGPT may be
prompted to go through the RoB 2.0 signalling questions. Future research may address the usefulness of

having systematic reviewers reconcile their risk of bias assessments with ChatGPT or the role of ChatGPT
in training systematic reviewers.

There are also opportunities to use ChatGPT to streamline other aspects of systematic reviews. Early
studies suggest that ChatGPT can be used to devise search strategies (44). ChatGPT may also assist with
screening search records, extracting data from eligible studies, or performing evaluations of the
certainty of evidence. Though, at this time, based on the results of the current study, we are not
optimistic about ChatGPT's ability to reliably extract data or evaluate the certainty of evidence.
Screening studies is less subjective and perhaps better suited to ChatGPT's abilities.

If ChatGPT's performance improves or if other tools emerge that can reliably perform various systematic
review tasks, systematic review authors will need to consider whether the time and resource savings
afforded by these tools are worth potential suboptimal performance. While these tools may not always
perform perfectly, they may still be useful in situations in which systematic reviews need to be
performed quickly or with limited resources. Similarly, systematic review authors will also need to
consider the acceptability of such tools by evidence users. For example, evidence users may be skeptical
of systematic reviews that use AI tools.

The integration of artificial intelligence and large language models in systematic reviews can also affect
trust in health research. We anticipate that due to limited experience, evidence users will be more
cautious about the application of studies that use such tools (45, 46).

**Conclusion**

We performed a study evaluating the usefulness of ChatGPT for assessing the risk of bias of parallel
randomized trials using the Cochrane-endorsed RoB 2.0 tool. We found only slight to fair agreement
between ChatGPT risk of bias judgements and risk of bias judgements presented in systematic reviews.
Our results suggest that ChatGPT, at least as it stands today, is suboptimal for performing risk of bias
assessments. The practice of evidence-based medicine demands knowledge of the best available
evidence, which most often comes from rigorous systematic reviews. Systematic reviews, though, are
time and resource intensive. Tools to assist with systematic reviews, be it with risk of bias assessments
or other tasks, are critically needed.

**Tables**

**Table 1: Characteristics of included systematic reviews**

| | |
|---|---|
| **Publication year** | |
| 2022 | 12 (35.9%) |
| 2023 | 22 (64.7%) |
| **Type of intervention** | |
| Pharmacologic | 18 (52.9%) |
| Surgical | 6 (17.6%) |
| Rehabilitation | 1 (2.9%) |
| Lifestyle | 4 (11.8%) |
| Other | 5 (14.7%) |
| **Type of condition** | |
| Infectious diseases | 9 (26.5%) |
| Ophthalmologic | 7 (20.6%) |
| Respiratory | 4 (11.8%) |
| Cardiac | 2 (5.9%) |
| Psychiatric | 2 (5.9%) |
| Gastrointestinal | 2 (5.9%) |
| Injury and poisoning | 1 (2.9%) |
| Pediatrics | 1 (2.9%) |
| Cancer | 1 (2.9%) |
| Endocrine | 1 (2.9%) |
| Neurologic | 1 (2.9%) |
| Other | 3 (8.8%) |
| **Type of risk of bias assessment** | |
| Assignment to the intervention | 24 (%) |
| Adherence to the intervention | 0 (0%) |
| Not reported | 10 (%) |
| **Type of outcome*** | |
| Dichotomous | 179 (65.3%) |
| Continuous | 95 (34.7%) |
| **Subjectivity of outcomes*** | |
| Definitely objective | 108 (39.4%) |
| Probably objective | 54 (19.7%) |
| Probably subjective | 64 (23.4%) |
| Definitely subjective | 48 (17.5%) |
| **Number of trials included per systematic review** median [IQR] | 3 [2 to 7] |

*For each review, we included data on more than one outcome.

**Table 2: Degree of Agreement**

| | | Consensus based risk of bias judgements reported in systematic reviews | | |
|---|---|---|---|---|
| | | Low risk of bias | Some concerns | High risk of bias |
| **Optimized ChatGPT prompt** | **Low risk of bias** | 4 (2.55%) | 2 (1.27%) | 0 (0%) |
| | **Some concerns** | 41 (26.11%) | 71 (45.22%) | 33 (21.02%) |
| | **High risk of bias** | 0 (0%) | 2 (1.27%) | 4 (2.55%) |
| **Minimal ChatGPT prompt** | **Low risk of bias** | 3 (1.91%) | 5 (3.18%) | 1 (0.64%) |
| | **Some concerns** | 42 (26.75%) | 66 (42.04%) | 32 (20.38%) |
| | **High risk of bias** | 0 (0%) | 3 (1.91%) | 4 (2.55%) |
| **Maximal ChatGPT prompt** | **Low risk of bias** | 1 (0.64%) | 2 (1.27%) | 0 (0%) |
| | **Some concerns** | 44 (28.03%) | 72 (45.86%) | 31 (19.75%) |
| | **High risk of bias** | 0 (0%) | 1 (0.64%) | 6 (3.82%) |

**Table 3: Weighted kappa values representing the degree of agreement between ChatGPT prompts and systematic review risk of bias judgements**

| | Optimized prompt | Minimal prompt | Maximal prompt |
|---|---|---|---|
| | Weighted kappa (95% CI) | | |
| Overall risk of bias rating | 0.17 (0.02, 0.32) | 0.11 (-0.04, 0.27) | 0.16 (0.01, 0.3) |
| Risk of bias due to randomization | 0.24 (0.02, 0.47) | 0.09 (-0.16, 0.33) | 0.09 (-0.15, 0.34) |
| Risk of bias due to deviations from the intended intervention | 0.11 (-0.11, 0.33) | 0.12 (-0.12, 0.37) | 0.12 (-0.13, 0.36) |
| Risk of bias due to missing outcome data | 0.29 (0.14, 0.44) | 0.23 (0.02, 0.45) | 0.16 (-0.05, 0.36) |
| Risk of bias due to measurement of the outcome | 0.14 (-0.13, 0.41) | 0.04 (-0.18, 0.25) | 0.05 (-0.18, 0.28) |
| Risk of bias due to selective reporting | 0.17 (-0.03, 0.37) | 0.29 (0.08, 0.49) | 0.21 (0.04, 0.37) |

**Figures**

***Figure 1: Overview of methods***

455
456

457 ***Figure 2: Screening process***

460    *Figure 3: Flow diagram representing changes in risk of bias judgements*
461

The bars on the left represent ratings of low risk of bias (represented in green), some concerns
(represented in orange), and high risk of bias (represented in red) by Cochrane systematic reviewers.
The bars on the right represent ratings of low risk of bias, some concerns, and high risk of bias by
ChatGPT. The graph represents differences in ratings of overall risk of bias between Cochrane systematic
reviewers and ChatGPT.

Cochrane systematic reviewers rated comparable proportions of trials at low risk of bias, some
concerns, and high risk of bias. Conversely, ChatGPT rated few trials at low and high risk of bias and
most trials as having some concerns.

**References**

1.    Guyatt, G. H., Rennie, D., Meade, M. O., & Cook, D. J. (2015). Users' guides to the medical literature⁠: essentials of evidence-based clinical practice (Third edition.). McGraw-Hill Medical.
2.    Michelson M, Reuter K. The significant cost of systematic reviews and meta-analyses: A call for greater involvement of machine learning to assess the promise of clinical trials. Contemp Clin Trials Commun. 2019;16:100443.
3.    Borah R, Brown AW, Capers PL, Kaiser KA. Analysis of the time and workers needed to conduct systematic reviews of medical interventions using data from the PROSPERO registry. BMJ Open. 2017;7(2):e012545.
4.    Nussbaumer-Streit B, Ellen M, Klerings I, Sfetcu R, Riva N, Mahmić-Kaknjo M, et al. Resource use during systematic review production varies widely: a scoping review. J Clin Epidemiol. 2021;139:287-96.
5.    Shojania KG, Sampson M, Ansari MT, Ji J, Doucette S, Moher D. How quickly do systematic reviews go out of date? A survival analysis. Ann Intern Med. 2007;147(4):224-33.
6.    Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
7.    Crocker TF, Lam N, Jordão M, Brundle C, Prescott M, Forster A, et al. Risk-of-bias assessment using Cochrane's revised tool for randomized trials (RoB 2) was useful but challenging and resource-intensive: observations from a systematic review. J Clin Epidemiol. 2023;161:39-45.
8.    Farrah K, Young K, Tunis MC, Zhao L. Risk of bias tools in systematic reviews of health interventions: an analysis of PROSPERO-registered protocols. Syst Rev. 2019;8(1):280.
9.    Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of randomized controlled trials: An annotated bibliography of scales and checklists. Controlled Clinical Trials. 1995;16(1):62-73.
10.    Barker TH, Stone JC, Sears K, Klugar M, Tufanaru C, Leonardi-Bee J, et al. The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evid Synth. 2023;21(3):494-506.
11.    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
12.    Critical Appraisal Skills Program (CASP). Critical Appraisal Checklists    [Available from: https://casp-uk.net/casp-tools-checklists/.
13.    Clark HD, Wells GA, Huët C, McAlister FA, Salmi LR, Fergusson D, Laupacis A. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials. 1999;20(5):448-52.
14.    Berger VW. Is the Jadad score the proper evaluation of trials? J Rheumatol. 2006;33(8):1710-1; author reply 1-2.
15.    Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
16.    Minozzi S, Cinquini M, Gianola S, Gonzalez-Lorenzo M, Banzi R. The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application. J Clin Epidemiol. 2020;126:37-44.
17.    Marshall IJ, Kuiper J, Wallace BC. RobotReviewer: evaluation of a system for automatically assessing bias in clinical trials. Journal of the American Medical Informatics Association. 2016;23(1):193-201.
18.    Arno A, Thomas J, Wallace B, Marshall IJ, McKenzie JE, Elliott JH. Accuracy and Efficiency of Machine Learning-Assisted Risk-of-Bias Assessments in "Real-World" Systematic Reviews : A Noninferiority Randomized Controlled Trial. Ann Intern Med. 2022;175(7):1001-9.

19.     Jardim PSJ, Rose CJ, Ames HM, Echavez JFM, Van de Velde S, Muller AE. Automating risk of bias assessment in systematic reviews: a real-time mixed methods comparison of human researchers to a machine learning system. BMC Med Res Methodol. 2022;22(1):167.

20.     Khalil H, Ameen D, Zarnegar A. Tools to support the automation of systematic reviews: a scoping review. Journal of Clinical Epidemiology. 2022;144:22-42.

21.     Lee P, Bubeck S, Petro J. Benefits, Limits, and Risks of GPT-4 as an AI Chatbot for Medicine. N Engl J Med. 2023;388(13):1233-9.

22.     Kottner J, Audigé L, Brorson S, Donner A, Gajewski BJ, Hróbjartsson A, et al. Guidelines for Reporting Reliability and Agreement Studies (GRRAS) were proposed. J Clin Epidemiol. 2011;64(1):96-106.

23.     Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71.

24.     Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-94.

25.     Pitre T, Mah J, Roberts S, Desai K, Gu Y, Ryan C, et al. Comparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea : A Systematic Review and Network Meta-analysis. Ann Intern Med. 2023;176(5):676-84.

26.     Pitre T, Jassal T, Angjeli A, Jarabana V, Nannapaneni S, Umair A, et al. A comparison of the effectiveness of biologic therapies for asthma: A systematic review and network meta-analysis. Ann Allergy Asthma Immunol. 2023;130(5):595-606.

27.     Pitre T, Van Alstine R, Chick G, Leung G, Mikhail D, Cusano E, et al. Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis. Cmaj. 2022;194(28):E969-e80.

28.     Rotondi MA, Donner A. A confidence interval approach to sample size estimation for interobserver agreement studies with multiple raters and outcomes. J Clin Epidemiol. 2012;65(7):778-84.

29.     Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull. 1968;70(4):213-20.

30.     Rao JN, Scott AJ. A simple method for the analysis of clustered binary data. Biometrics. 1992;48(2):577-85.

31.     Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-74.

32.     William Revelle (2023). psych: Procedures for Psychological, Psychometric, and Personality Research. Northwestern University, Evanston, Illinois. R package version 2.3.9, https://CRAN.R-project.org/package=psych.

33.     Ely EW, Ramanan AV, Kartman CE, de Bono S, Liao R, Piruzeli MLB, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10(4):327-36.

34.     Lisa H, Maria O, Yuanyuan L, Donna MD, Nicola H, Jennifer Krebs S, Terry PK. Risk of bias versus quality assessment of randomised controlled trials: cross sectional study. BMJ. 2009;339:b4012.

35.     Wu T, He S, Liu J, Sun S, Liu K, Han QL, Tang Y. A Brief Overview of ChatGPT: The History, Status Quo and Potential Future Development. IEEE/CAA Journal of Automatica Sinica. 2023;10(5):1122-36.

36.     Shahriar S, Hayawi K. Let's have a chat! A Conversation with ChatGPT: Technology, Applications, and Limitations. arXiv preprint arXiv:230213817. 2023.

37.     Bertizzolo L, Bossuyt P, Atal I, Ravaud P, Dechartres A. Disagreements in risk of bias assessment for randomised controlled trials included in more than one Cochrane systematic reviews: a research on research study using cross-sectional design. BMJ Open. 2019;9(4):e028382.

38.     Hartling L, Hamm MP, Milne A, Vandermeer B, Santaguida PL, Ansari M, et al. Testing the risk of
bias tool showed low reliability between individual reviewers and across consensus assessments of
reviewer pairs. J Clin Epidemiol. 2013;66(9):973-81.

39.     Windsor B, Popovich I, Jordan V, Showell M, Shea B, Farquhar C. Methodological quality of
systematic reviews in subfertility: a comparison of Cochrane and non-Cochrane systematic reviews in
assisted reproductive technologies. Human Reproduction. 2012;27(12):3460-6.

40.     Petticrew M, Wilson P, Wright K, Song F. Quality of Cochrane reviews. Quality of Cochrane
reviews is better than that of non-Cochrane reviews. Bmj. 2002;324(7336):545.

41.     Abdullah M, Madain A, Jararweh Y, editors. ChatGPT: Fundamentals, Applications and Social
Impacts. 2022 Ninth International Conference on Social Networks Analysis, Management and Security
(SNAMS); 2022 29 Nov.-1 Dec. 2022.

42.     OpenAI. ChatGPT — Release Notes: The latest update for ChatGPT 2024 [Available from:
https://help.openai.com/en/articles/6825453-chatgpt-release-notes.

43.     Sun S. Meta-analysis of Cohen's kappa. Health Services and Outcomes Research Methodology.
2011;11(3):145-63.

44.     Wang S, Scells H, Koopman B, Zuccon G. Can ChatGPT write a good boolean query for systematic
review literature search? arXiv preprint arXiv:230203495. 2023.

45.     Temsah MH, Aljamaan F, Malki KH, Alhasan K, Altamimi I, Aljarbou R, et al. ChatGPT and the
Future of Digital Health: A Study on Healthcare Workers' Perceptions and Expectations. Healthcare
(Basel). 2023;11(13).

46.     Noura A, Khalid A, Rupesh R, Khalid AM, Fadi A, Ibraheem T, et al. Exploring Perceptions and
Experiences of ChatGPT in Medical Education: A Qualitative Study Among Medical College Faculty and
Students in Saudi Arabia. medRxiv. 2023:2023.07.13.23292624.